Compare Eaton Corporation plc (ETN) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs GSK plc — how do they compare? Eaton Corporation plc trades at $429.65 (market cap $164.88B), while GSK plc trades at $46.54 (market cap $91.88B). The key difference: Eaton Corporation plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 31 Days and GSK plc for 93 Days on average.
| ETN | GSK | |
|---|---|---|
Market Cap | $164.88B | $91.88B |
Volume | 2,535,086 | 7,730,529 |
Sector | Industrials | Health |
52-Week High | $459.96 | $61.18 |
52-Week Low | $315.82 | $43.24 |
Typical Hold Time | 31 Days | 93 Days |
Enterprise Value | $185.51B | $111.88B |
Dividend Yield | 1.04% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $429.65, down 0.39% on the day, with technical indicators showing a bearish bias despite recent earnings beats. The company maintains strong fundamentals with 12.75% net income margin and 19.71% ROE, supported by strategic acquisitions in data center and aerospace markets. Analyst consensus remains strongly bullish with a $502.38 price target, representing 17% upside potential from current levels.
ETN's outlook remains positive driven by data center demand and grid modernization trends, though elevated valuation multiples (P/E 43.23) and bearish technical signals warrant caution. The stock faces execution risks from recent acquisitions and competitive pressure in the electrical equipment sector, but strong institutional support and consistent earnings performance support the bullish analyst stance.
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
